Market
Will Lenacapavir become available in at least 10 countries by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from relevant health ministries or pharmaceutical companies
Story
Lenacapavir: New Injectable HIV Drug Offers 96-100% Efficacy with Twice-Yearly Dosing, Recognized as Scientific Breakthrough
Dec 30, 2024, 01:30 PM
A new injectable antiretroviral drug, Lenacapavir, has been recognized as a potential breakthrough in the fight against HIV and AIDS. According to reports, it boasts an efficacy rate of 96-100% and offers a twice-yearly dosing schedule, which could significantly enhance treatment accessibility and adherence. This innovation has been highlighted by the journal 'Science' as a scientific breakthrough of the year, with the potential to curb new HIV infections globally. Discussions around its availability and implementation are ongoing, as stakeholders consider the implications of this advancement in HIV prevention and treatment.
View original story
Similar markets
Other • 25%
European Union • 25%
United States • 25%
South Africa • 25%
5-9 countries • 25%
1-4 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
Africa • 25%
Asia • 25%
North America • 25%
Europe • 25%
No • 50%
Yes • 50%
Southeast Asia • 25%
Sub-Saharan Africa • 25%
Other • 25%
South America • 25%